

3. (AMENDED) The method according to claim 2, [characterized in that] wherein
the allergen [correspond] corresponds to a non-secreted protein from A. fumigatus.

Sub C2 4. (AMENDED) The method according to claim 1, wherein the [anyone of claims
1-3, characterized in that said] one or more allergens are selected [among] from the group
consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.

Sub G1 5. (AMENDED) The method according to claim 1, wherein the [anyone of claims
1-3, characterized in that said] one or more allergens are selected [among] from the group
consisting of rAsp f8 and ABPA-related fragments thereof

Sub G1 6. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-4,
characterized in that] an in vitro immunoassay is carried out on a fluid sample from the
individual for the determination of the level of antibodies directed towards said recombinant
allergens[, in particular antibodies of the IgE class or IgG class or subclasses thereof].

7. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-5,
characterized in that] antibodies of the IgE class are determined.

Sub G2 8. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-4,
characterized in that] an in vivo test is carried out in the individual.

Sub C3 9. (AMENDED) The method according to claim 7, [characterized in that] wherein
the test is a skin test involving placing said one or more ABPA-related allergens in the skin of
the patient.

10. (AMENDED) The method according to claim 9, [characterized in that] wherein
an in vitro immunoassay is carried out on a fluid sample from the individual for the
determination of the level of antibodies directed towards said recombinant allergens[, in
particular antibodies of the IgE class or IgG class or subclasses thereof].

G1
8. (AMENDED) The method according to claim 16, [characterized in that] wherein antibodies of the IgE class are determined.

9. (AMENDED) The method according to claim 5, [characterized in that] wherein an in vivo test is carried out in the individual.

10. (AMENDED) The method according to claim 12, [characterized in that] wherein the test is a skin test involving placing said one or more ABPA-related allergens in the skin of the patient.

Please add the following claims 14-20:

11. --14. (NEW) The method according to claim 6, wherein antibodies of the IgE class or IgG class, or subclasses thereof, are determined.--

12. --15. (NEW) The method according to claim 10, wherein antibodies of the IgE class or IgG class, or subclasses thereof, are determined.--

--16. (NEW) The method according to claim 2, wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.--

--17. (NEW) The method according to claim 3, wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.--

--18. (NEW) The method according to claim 2, wherein the one or more allergens are selected from the group consisting of rAsp f8, and ABPA-related fragments thereof.--

--19. (NEW) The method according to claim 3, wherein the one or more allergens are selected from the group consisting of rAsp f8, and ABPA-related fragments thereof.--

17. --20. (NEW) The method according to claim 18, wherein an in vivo test is carried out in the individual.--